Lisofylline mitigates cardiac inflammation in a mouse model of obesity through improving insulin secretion and activating cardiac AMPK signaling pathway.
Sign Up to like & getrecommendations! Published in 2020 at "Cytokine"
DOI: 10.1016/j.cyto.2020.155398
Abstract: Obesity has emerged as a leading cause of death in the last few decades, mainly due to associated cardiovascular diseases. Obesity, inflammation, and insulin resistance are strongly interlinked. Lisofylline (LSF), an anti-inflammatory agent, demonstrated protection… read more here.
Keywords: inflammation; cardiac ampk; obesity induced; cardiac inflammation ... See more keywords